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Abstract 
 
 The nematode C. elegans exhibits SL1 trans-splicing, a unique form of pre-mRNA 
processing seen in a variety of lower metazoans. In C. elegans, there are two types of trans-
spliced leader that are added onto the 5' end of trans-spliced pre-mRNA: SL2 and its 
evolutionary predecessor, SL1. A bioinformatic analysis by Graber et al. (2007) revealed two 
conserved sequences associated with SL2 and SL1-accepting pre-mRNA known as the “Ur” and 
“Ou elements” respectively. Lasda et al. (2010) demonstrated that the Ur element is required for 
SL2 trans-splicing and predicted that the Ou element functions similarly for SL1 trans-splicing. 
The present study investigated the role of the Ou element in SL1 trans-splicing by gathering 
primary data using mutational analysis followed by SL1 in vitro trans-splicing assays. Two 
different Ou-mutations considerably decreased SL1 trans-splicing efficiency when compared to 
wild-type constructs of the same gene. These data suggest that the Ou element may play a key 
role in SL1 trans-splicing.  
 
 
 
 
 
 
 
 
Gallegos, 3 
 
Introduction 
 
 The nematode Caenorhabditis elegans is commonly used in studies of cellular and 
molecular biology (Blumenthal & Spieth, 1996).  Although it is a eukaryote, the C. elegans 
genome is small, “enabling [scientists] to view the entire array of genes required to build a 
complex, multicellular animal” (Blumenthal & Spieth, 1996).  Like those of higher eukaryotes, 
C. elegans genes are monocistronic (each mRNA encodes only one protein); however, they 
express an unusual feature of pre-mRNA processing also observed in trypanosomes and other 
lower metazoans (Spieth et al., 1993). Many C. elegans genes undergo unique intermolecular 
ligations involving the 5’ splice site of one RNA and the 3’ splice site of another, termed trans-
splicing (Hirsh & Krause, 1987). SL trans-splicing in C. elegans involves the transfer of a short, 
conserved leader sequence from the 5’ end of a spliced leader (SL RNA) to the 5’-most exon of a 
pre-mRNA (Nielsen, 1993; Blumenthal, 2005; Hastings 2005). The leader sequence has been 
proposed to serve a number of possible functions in the mRNA preceding and including 
translation, but the specific purpose of SL1 trans-splicing is not known (Lall et al., 2004). SL1 
trans-splicing is highly conserved in the nematode phylum. Within C. elegans, 70% of mRNAs 
are trans-spliced (Spieth et al., 1993).  
 Krause and Hirsch (1987) described the discovery of a unique 22 nucleotide (nt) leader 
sequence at the 5’ end of three actin mRNA in C. elegans. The sequence was reminiscent of the 
35 nt leader that is trans-spliced onto trypanosome mRNA. Krause and Hirsch (1987) ran several 
tests to eliminate alternative mechanism hypotheses, such as cis-splicing or primed transcription, 
and suggested that the 22 nt sequence was trans-spliced onto the ends of actin pre-mRNA. They 
tracked the source of the leader sequence to a novel 100 nt small nuclear RNA (snRNA). The 
Gallegos, 4 
 
snRNA is part of a complex now known as the SL1 small nuclear ribonucleoprotein (snRNP) 
(Blumenthal, 2005). The snRNA was trans-spliced onto the 5’ end of the actin mRNA. The 
process of replacing upstream pre-mRNA sequence with this conserved 22 nt sequence is termed 
SL1 trans-splicing (Blumenthal and Spieth, 1996). 
 Pre-mRNA transcripts that will be trans-spliced differ from those that will not by the 
presence of an outron (Blumenthal, 2005). The outron resembles an intron (non-coding pre-
mRNA that is removed by cis-splicing in eukaryotes), but consists of the RNA from the 
transcription start site to the 5’ end of the first exon and is removed by SL1trans-splicing 
(Blumenthal & Spieth, 1996). The outron is replaced by a common 22 nt sequence known as the 
spliced leader that is not present in the genomic DNA for that gene (Hirsh & Krause, 1987). The 
spliced leader is donated by a 100 nt RNA contained within the SL1 snRNP (Blumenthal, 2005). 
The 5’ splice site on the SL RNA and the 3’ splice site on the pre-mRNA closely resemble the 5’ 
and 3’ consensus intronic splice sites that function in cis-splicing (Kent and Zahler, 2000). In cis-
splicing, the U1 snRNP recognizes the 5’splice site on the pre-mRNA via a base-pairing 
interaction (Spieth et al., 1993). Trans-splicing is mechanistically similar to cis-splicing; 
however, the spliced leader and, therefore, the 5’ splice site is attached to the SL snRNP. In this 
case, it is the SL-accepting pre-mRNA that is predicted to recognize the 5’ splice site by base-
pairing (Lasda et al. 2010). This proposed interaction is modeled in Figure 0. 
 Spieth et al. (1993) discussed the gene arrangement that causes some pre-mRNAs to 
trans-splice to a second class of spliced leader, SL2, instead of its evolutionary predecessor SL1. 
Like bacteria, some C. elegans genes exist in clusters controlled by the same promoter known as 
operons; however, C. elegans RNA is processed prior to translation into single-gene units 
separated by a combination of 3’ end formation and trans-splicing. Genes downstream in an 
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operon are trans-spliced to SL2. To prove this, Spieth et al. (1993) moved an SL1 accepting gene 
to a location downstream in an operon and observed that the gene was then spliced to SL2. These 
results suggest that “this chromosomal arrangement is necessary and sufficient for SL2 trans-
splicing.” (Speith et al. 1993) 
 Another study suggests that while a location downstream in an operon is a prerequisite 
for SL2 trans-splicing, it may not be sufficient. As described above, the U1 snRNP acts in cis-
splicing (removal of introns) by base pairing with a complementary sequence at the 5’ splice site. 
Lasda et al. (2010) proposed that a U-rich region of the pre-mRNA acts by a similar mechanism 
in recognizing the 5’ splice site on the SL2 snRNP. In 2007, Graber et al. performed a statistical 
analysis of the sequences of genes that are SL1 and SL2 trans-spliced in hopes of finding trends 
to differentiate between pre-mRNA that is not trans-spliced, SL1 trans-spliced, and SL2 trans-
spliced. They further defined this evolutionarily conserved U-rich region (first identified by 
Huang et al. 2001) common among SL2 trans-spliced genes termed the “Ur element”.  In 2010, 
Lasda et al. used mutational analysis and bioinformatics to more specifically describe the Ur 
element as a short stem loop followed by the sequence UAYYUU (where Y represents a 
Cytosine or Uracil) located approximately 50 nt upstream of the SL2 trans-splice site that is 
necessary for SL2-specific trans-splicing. The Ur element is predicted to act by base-pairing with 
the SL2 trans-splice site on the SL2 snRNP (Lasda et al., 2010).  
 Lasda et al. (2010) and Graber et al. (2007) also discussed a common outron-specific 
sequence of SL1 trans-spliced pre-mRNA known as the “Ou element”.  The Ou element is 
characterized by a UC-rich region approximately 50 nt upstream of the SL1 trans-splice site. 
Specifically the consensus sequence URYYUY (where R represents an Adenine or a Guanine), 
or one closely related, appears to be associated with SL1 trans-spliced pre-mRNA. Lasda et al. 
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(2010) suggested that the Ur element exemplifies a common mechanism for SL2 trans-splicing, 
and hypothesized that the Ou element may be the SL1 equivalent.  
 The SL1 and SL2 RNAs in complex with the snRNP’s are of similar length and share 
much of the same composition. Both contain a 22 nt SL exon and an Sm protein binding site 
(Blumenthal, 2005).The secondary structure of both SL RNAs is predicted to consist of three 
stem-loops with a 5’ trimethylguanine cap (Blumenthal, 2005). SL1 RNA differs from SL2 RNA 
in its association with the trans-splicing specific proteins sna-1 and sna-2. Further, the SL2 
snRNP is unique in its interaction with 3’ end formation factor CstF-64 (MacMoris et al. 2007). 
Nonetheless, despite their specificity to different types of gene arrangements, SL1 and SL2 trans-
splicing machinery is very similar. It is, therefore, reasonable to predict that a consensus 
sequence exists for SL1 trans-splicing that is analogous to the Ur element in SL2 trans-splicing. 
 It is predicted that the Ou element base pairs with the SL1 trans-splice site on the SL1 
snRNA in a necessary role similar to that of the Ur element for SL2 trans-splicing. Unlike the Ur 
element, however, little work has been done to experimentally define or verify the role of the Ou 
element in trans-splicing. Bioinformatics and the existence of a complementary sequence on the 
SL1 snRNP leads to the prediction that the Ou element is defined by the consensus sequence 
URYYUY. This hypothesis is further supported by the frequency at which this combination 
appears in SL1 trans-spliced genes according to bioinformatics (Graber et al., 2007). Figure 0 
demonstrates a model for the proposed interaction between the Ou element and the 5’ trans-
splice site on the SL1 RNA.   
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Figure 0: Model for the interaction between the Ou element in the outron of SL1 trans-spliced mRNA and the SL1 
snRNP complex. 
 
 Despite the prevalence C. elegans research, much still needs to be elucidated about the C. 
elegans-specific process of SL1 trans-splicing. Studies have discovered novel proteins involved 
in trans-splicing, and bioinformatics analysis of trans-spliced genes has identified the Ur and Ou 
elements, but questions remain about the specific mechanisms of trans-splicing. This project 
examines the role of the Ou element in SL1 trans-splicing. C. elegans is important as a model 
organism and is frequently studied with reference to human health. Thus, C. elegans research 
investigating trans-splicing will contribute to the understanding of this process and may have 
practical applications as well.  
 In this study, the role of the Ou element in SL1 trans-splicing was investigated in vitro. 
First, the outron of an gene SL1 trans-spliced gene was defined and a potential Ou element was 
identified. This gene, nduf2.2 (T26A5.3) is predicted to encode a mitochondrial protein. Then, 
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two different mutations were created in the outron of the gene nduf2.2 disrupting the proposed 
Ou consensus. An in vitro trans-splicing assay was used to compare the trans-splicing 
competency of the wild-type construct versus the two mutant constructs. A decrease in SL1 
trans-spliced product in mutant constructs would indicate that the Ou element plays a role in 
trans-splicing, and when the consensus is interrupted, it does so less efficiently. If the Ou 
element is necessary for trans-splicing, a decrease in trans-splicing efficiency was predicted to 
occur when the proposed Ou consensus was disrupted.  
  It was observed from the in vitro reactions comparing wild-type and mutant constructs 
that mutating the Ou element considerably decreased the yield of SL1 trans-spliced product. 
These results were consistent among multiple trans-splicing reactions and two separate mutants. 
These data indicate that the Ou element was correctly identified for the gene nduf2.2 and that it is 
in fact necessary for SL1 trans-splicing in vitro.  
 
Materials and Methods 
 
I. Defining outron length 
   To analyze the importance of the Ou element, it was necessary to identify a good 
candidate gene for study. An ideal gene splices exclusively to SL1, has a short outron (to limit 
the number of possible matches to the Ou consensus sequence), and has a close or perfect match 
to the sequence URYYUY. The efficiency of trans-splicing and the lack of a TATA box in many 
C. elegans genes has made it difficult to identify promoters; thus, the length of most outrons 
have not been determined (Blumenthal and Spieth, 1996). 
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 To select candidate genes for this study, I aligned RNA Polymerase II ChIP-sequence 
data from Baugh et al. (2009) with the nematode genome in the UCSC Genome Browser. The 
ChIP sequence data maps the association of polymerase II with the C. elegans genome. Based on 
the data of Morton and Blumenthal (2010), it was predicted that a large polymerase peak 
upstream of a gene is indicative of the location where polymerase paused at the promoter and, 
therefore, the approximate 5’ end of the outron. A good candidate would be SL1-accepting and 
have a large well-defined polymerase peak very close to, but just upstream of, the trans-splice 
site. After selecting five candidate genes with predicted outrons of less than 400 base pairs (bp) 
by this mechanism, I researched the genes on WormBase to confirm that they were trans-spliced 
to SL1 and not to SL2. 
 To verify the actual length of the outrons of the five candidate genes (alh-9, rpn-2, 
F52C9.7, C16A3.6, and nduf-2.2), I used extracted RNA from C. elegans nematodes. I 
performed reverse transcription (RT) reactions on the mRNA from each of the five SL1 
accepting genes to procure cDNA from the lysed nematode RNA. Reverse primers in the second 
exon and Superscript II (Invitrogen) were used. For each gene, I designed multiple forward 
primers to amplify the cDNA by polymerase chain reaction (PCR) at increasing distances 
upstream of the 5’ end of the first exon (well beyond the expected length of the outron) and 
reverse primers in a downstream exon. Taq polymerase (Invitrogen) was used to amplify the 
cDNA. Presumably, only primers within the original outron of the gene would be extended to 
produce a product. Furthermore, since the primers spanned an intron, I would be able to see to 
what extent splicing had already occurred in the RNA samples. A separate PCR reaction was 
performed for each forward primer and the product was run on an agarose gel stained with 
ethidium bromide. For each gel, there were two negative controls, a blank containing water in 
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place of cDNA and one containing an RT product in which the enzyme Super Script II had been 
replaced with water to ensure that genomic DNA was not being amplified in the sample. A 
positive control containing genomic DNA instead of cDNA was also used to ensure all primers 
were binding specifically and efficiently. 
 The following Figures 1.1-1.4 contain the results for all genes not selected for study (all 
except nduf2.2 which is examined in more detail in the results section). The primers are named 
for the distance from their 3’ end to the 5’ end of the first exon. Primer lengths are not to scale 
and only primers within the expected outron length based on the Baugh et al. data (2009), ergo 
primers downstream of the polymerase peak, are correctly aligned with the figures. These genes 
were not chosen because their outron length, according to the RT-PCR data, exceeded that of 
nduf2.2.  
 
 
Figure 1.1. Alh-9 has an outron greater than 139 bp in length 
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Figure 1.2. Rpn-2 has an outron greater than 203 bp in length 
 
 
Figure 1.3. F52C9.7 has an outron greater than 191 bp in length 
 
Gallegos, 12 
 
 
Figure 1.4. C16A3.6  has an outron greater than 183 bp in length 
 
II. Cloning and mutating nduf2.2 
 To create wild-type and mutant constructs, I first amplified genomic DNA corresponding 
to nduf2.2 from C. elegans wild-type populations using pfx polymerase (Invitrogen). I then 
cloned a fragment from 111 nt upstream of the first exon to 31 nt downstream of the third exon 
into the EcoRV and KpnI restriction sites of pBluescript SK- plasmid, making a wild-type 
nduf2.2 construct. I then used PCR mutagenesis to introduce substitution mutations to the 
prospective Ou elements using pfx polymerase (Invitrogen) and standard PCR cloning 
techniques. The sequences of the wild-type and mutant constructs were confirmed by DNA 
sequencing (wild-type and mutant constructs are summarized in Figure 5). 
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III. In vitro transcription and trans-splicing 
  Mutant and wild-type plasmids were linearized with XbaI and purified using a Qiagen 
MinElute PCR Purification Kit. Mutant and wild-type DNA constructs were transcribed in vitro 
using a T7 RNA Polymerase mMessage mMachine Kit (Ambion). Samples were then 
polyadenylated by an Ambion/Applied biosystems Poly(A) Tailing kit. RNA was isolated by 
phenol/chloroform extraction and isopropanol precipitation, resuspended, and purified by 
Ambion/Applied Biosystems NucAway Spin columns. The in vitro trans-splicing system was set 
up as described in Lasda et al. 2010. Briefly: 25 ng (for most samples though a gradient of 5, 10, 
15, and 25 ng was also used for one trial) mutant or wild-type RNA substrate was added to a 15 
ul reaction of 50% C. elegans embryonic extract capable of splicing. The extract contained 
endogenous SL1 and SL2 complexes as well as trans-splicing machinery. ATP- samples lacking 
ATP, creatine phosphate, and creatine phosphokinase were set up in parallel to ensure that 
products obtained are ATP-dependent and, therefore, a product of the splicing reaction. Samples 
were incubated at 15˚C for 2 hours before adding STOP buffer. Reactions were then digested by 
Proteinase K for 15 minutes at 37˚C and the RNA was isolated by phenol/chloroform extraction 
and ethanol precipitation. 
 
IV.  Analysis of spliced product 
 20% of the RNA from the splicing reactions was used in a 10ul RT Reaction with 
Invitrogen Superscript II and a reverse primer downstream of the gene in a pBluescript SK- 
region. 2ul of the RT reaction (0.5ul for IC samples) was amplified in 50ul PCR reactions. 
Reverse primers corresponded to a pBluescript SK- region downstream of the gene. Forward 
primers specific for SL1 (SL1 leader sequence + A) were used to amplify products that have 
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been SL1 trans-spliced. Samples were also primed for the SL2 sequence (SL2 leader sequence + 
A) to determine if SL2 trans-splicing takes over when SL1 trans-splicing decreases. Products in 
which the SL1leader sequence was trans-spliced to the 5’ end of the second exon were isolated 
by the 2E2 primer which contains the SL1 leader sequence plus the first several bases of exon 2. 
An internal portion of the second exon (IC) was used to amplify all nduf2.2 cDNA regardless of 
spliced status. Products isolated by these primers sets are examined in detail in the results 
section. Finally, cDNA minus controls contain no DNA in order to identify if there are any 
contaminants present in the PCR reaction. 
 12.5 ul of each PCR reaction was analyzed on a 2% agarose gel stained with ethidium 
bromide.  Quantitative comparisons were achieved using the volume select tool on the Quantity 
One software used to analyze the gels. These comparisons are expressed as ratios as they are 
determined from band intensity and the actual volume amounts are arbitrary. 
 
V.  PCR primers   
 
Oligo Name Gene Sequence (5'→ 3') purpose
alh_RT-Rev alh9 ACCTCGCACCAATCGTTATAAGCC candidate gene selection
alh9-Rev alh9 GAGATGGCGATTTCATAGTCTTGTACG candidate gene selection
alh9_up22-For alh9 ctaaTACCTTctgtttcaaagcgtctaac candidate gene selection
alh9_up55-For alh9 cttgttttttgaccactaacctcttcg candidate gene selection
alh9_up139-For alh9 cgtcgtcataaacaatctgcccg candidate gene selection
alh9_up192-For alh9 gatctgcaatctgtccttgaattcc candidate gene selection
alh9_up253-For alh9 tagccttgtatcatgttccacgtc candidate gene selection
rpn-2_RT-Rev rpn2 AAACTTTGGAGACGAGCAGTGC candidate gene selection
rpn2-Rev rpn2 GCGACCTCAAACCATGTGTTCAC candidate gene selection
rpn2_up23-For rpn2 cctagctgctctcatttcggattg candidate gene selection
rpn2_up88-For rpn2 gacgagaaagctgtttttctgataacctag candidate gene selection
rpn2_up141-For rpn2 gcctgattTATTTTTAgacgttttctaatttgtc candidate gene selection
rpn2_up164-For rpn2 ccattgttggtgtttgagtaattttatgattttc candidate gene selection
rpn2_up203-For rpn2 ttcgcaatcattcttttcgttcgg candidate gene selection
rpn2_up290-For rpn2 ggatgacaattctgaccacagc candidate gene selection
rpn2_up326-For rpn2 gctggcgcaattatcgattagttg candidate gene selection
rpn2_up460-For rpn2 gcggtcaaactagacaccaatacac candidate gene selection
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F52C9.7_RT-Rev F52C9.7 GAGGATTATCCATGATTTCCCGACG candidate gene selection
F52C9.7-Rev F52C9.7 TTTCTTCTCGAACCTTGACGGC candidate gene selection
F52C9.7_up80-For F52C9.7 gcgcaacgcgttttgaagtgta candidate gene selection
F52C9.7_up126-For F52C9.7 ccatggccgagttttgaccTATAttg candidate gene selection
F52C9.7_up164-For F52C9.7 caccaacaatggcctagaaccac candidate gene selection
F52C9.7_up191-For F52C9.7 ccttctccatttgaaataccgcg candidate gene selection
F52C9.7_up291-For F52C9.7 gctgctccttaacaccaaattcg candidate gene selection
F52C9.7_up319-For F52C9.7 gttttttggtttatatattagtatgagagcgatgg candidate gene selection
F52C9.7_up456-For F52C9.7 cccagcaacacatttcagcc candidate gene selection
C16A3.6_RT-Rev C16A3.6 GGCTAAGAGCTCTTTCTCAATAGCG candidate gene selection
C16A3.6_RT C16A3.6 GCAACAAGTGCCTTCTCTTCAC candidate gene selection
C16A3.6_UP5-For C16A3.6 ctcaaaaaattcgaatttttcagaaactggg candidate gene selection
C16A3.6_UP44-For C16A3.6 ctttttccttttatcgaagtaattctcgtgtg candidate gene selection
C16A3.6_UP87-For C16A3.6 caatttttttgcccgttcttctcaatc candidate gene selection
C16A3.6_UP119-For C16A3.6 gaagacgcacactttcggttc candidate gene selection
C16A3.6_UP177-For C16A3.6 gaaaatagagagaaggcgccttaagg candidate gene selection
C16A3.6_UP242-For C16A3.6 gtggcccagttatttcctgtg candidate gene selection
nduf2.2_RT-Rev nduf2.2 CCCTCATAATTGTCGCTGAGCAC candidate gene selection
nduf2.2_Rev nduf2.2 GGATACGCGTTCTGACATCCAAAG candidate gene selection
nduf2.2_UP0-For nduf2.2 caagtttaactgtaaattattactgtaaatttgttcagag candidate gene selection
nduf2.2_UP15-For nduf2.2 ctccttgaattttcaagtttaactgtaaattattactg candidate gene selection
nduf2.2_UP28-For nduf2.2 cgttttctccttgaattttcaagtttaactg candidate gene selection
nduf2.2_UP36-For nduf2.2 gttttacacgttttctccttgaattttcaag candidate gene selection
nduf2.2_UP49-For nduf2.2 gaaattagcaatatttgttttacacgttttctcc candidate gene selection
nduf2.2_UP66-For nduf2.2 cgactacggtagtatttgaaattagcaatatttg candidate gene selection
nduf2.2_UP91-For nduf2.2 caacgattgaaagcgactacgg candidate gene selection
nduf2.2_UP120-For nduf2.2 gcaaggagcaagtctcgagtag candidate gene selection
nduf2.2_UP149-For nduf2.2 gcgctaccttaatctttgaatagcc candidate gene selection
nduf2.2_UP256-For nduf2.2 ggcgtttgagaaagattaaaaagccc candidate gene selection
nduf2.2_KpnI-For nduf2.2 cgattgaaagcgactacggtagtatttg cloning nduf2.2
nduf2.2_EcoRV-Rev nduf2.2 CAAGACCTACACACAGgttgagtcgTaa cloning nduf2.2
T3-Rev pBSK TCCCTTTAGTGAGGGTTAAT mutating nduf2.2
T7-For pBSK GTAATACGACTCACTATAGgG mutating nduf2.2
n2uf2.2_mut1-For nduf2.2
GCAATAAAACAATTACACGTTTTCTTCTTGAATTTTCAAG
TTTAACTG
mutating nduf2.2 (mut 1)
n2uf2.2_mut1-Rev nduf2.2
GAAAACGTGTAATTGTTTTATTGCTAATTTCAAATACTAC
CGTAGTCG
mutating nduf2.2 (mut 1)
n2uf2.2_mut2-For nduf2.2
GCAATATTTACCTCACACGTTTTCTCCTTGAATTTTCAAG
TTTAACTG
mutating nduf2.2 (mut 2)
n2uf2.2_mut2-Rev nduf2.2
GAAAACCTGTGAGGTAAATATTGCTAATTTCAAATACTAC
CGTAGTCG
mutating nduf2.2 (mut 2)
pBSK_RT-Rev nduf2.2 ACTAGTGGATCCCCCGGGCTG RT of spl iced RNA
pBSK-Rev pBSK GAATTCCTGCAGCCCGGGGGATC PCR of spl iced cDNA
SL1 + A n/a ggtttaattacccaagtttgaga PCR of spl iced cDNA
SL2 + A n/a GGTTTTAACCCAGTTACTCAAGA PCR of spl iced cDNA
nduf2.2_2E2-For nduf2.2 GGTTTAATTACCCAAGTTTGAGACTG PCR of spl iced cDNA
nduf2.2_IC-For nduf2.2 GCGATCCGGTGCTCAGC PCR of spl iced cDNA
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Results 
 
I. Defining the outron length of nduf2.2 
 I examined the outron length of five genes and determined nduf2.2 to be the best 
candidate.  Figure 2 shows Chromatin Immunoprecipitation sequence data of RNA Polymerase 
from Baugh et al.(2009) aligned with the UCSC C. elegans genome browser for the gene 
nduf2.2. I predicted from the Baugh et al. (2009) data that nduf2.2 has an outron of 
approximately 80 bp. 
 
 
Figure 2. ChIP sequence data from Baugh et al. (2009) aligned with the UCSU genome browser 
(http://genome.ucsc.edu/). The center of the polymerase peak occurs approximately 80 bp upstream of the first exon. 
 
 In order to confirm the length of the outron, I reverse transcribed nduf2.2 RNA and 
amplified it using seven primers each at a different location upstream of the trans-splice site 
(Figure 4). RT-PCR data presented in Figure 4 confirm that the outron is approximately 80 bp in 
length. The lanes are labeled according to the distance of the 3’ end of the primer used to amplify 
the nduf2.2 cDNA from the trans-splice site. As explained in materials and methods, there are 
three samples for each primer: cDNA minus (negative controls containing no template DNA), 
the nduf2.2 cDNA sample, and genomic DNA (positive control to ensure primer precision). The 
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last primer to successfully amplify the nduf2.2 cDNA is 49 bp upstream of the first exon at its 3’ 
end and 84 bp upstream of the first exon at its 5’ end. This supports my prediction that the 
distance between the transcription start site and the SL1 trans-splice site of nduf2.2 is 
approximately 80 nt.  
 
 
Figure 3: Map of primers used to determine outron length. Oligos are named for the distance between their 3’ end 
and the trans-splice site. Oligo lengths are not to scale. 
 
 
Figure 4. Results from RT-PCR analysis of outron length of nduf2.2. The genomic DNA bands run slightly higher 
as they contain introns. Double bands in the cDNA lanes (as for oligo 49) indicate cis-spliced and non cis-spliced 
cDNA. cDNA samples are detectable by oligo 49 but not oligo 66 (as shown by arrows) indicating the 5’ end of the 
outron lies between these primers. 
 
II.  Comparing splicing for mutant and wild-type constructs 
  
 After identifying the outron for nduf2.2, Dr. Blumenthal, Dr. Morton, and I then searched 
the sequence for potential Ou elements. There is a perfect match for the predicted Ou element 
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(UGUUUU) 60 bp upstream of the trans-splice site as well as several nearby and/or over-lapping 
sequences that are one to two base mismatches from the Ou consensus. One or all of these 
sequences may interact independently or redundantly with the SL1 trans-splicing machinery and 
be required for SL1 trans-splicing. We then designed two different mutations to disrupt the Ou 
consensus. We also mutated two base-pairs just upstream of the proposed Ou element in order to 
also disrupt a one base mismatch to the consensus overlapping and just upstream with the 
sequence UAUUUG. Figure 5 shows the proposed Ou element and the sequence of both mutants. 
 
Figure 5: Sequences of wild-type (WT) and mutant (Mut) constructs across the potential Ou element from 49 to 76 
bp upstream of the SL1 trans-splice site. Mutated regions are in bold. The mutated bases are in red, the region of the 
potential Ou element is surrounded by a blue box, and the overlapping one base mismatch is underlined. 
 
 In order to define the role of the Ou element in nduf2.2, as Lasda et al. (2010) have for 
the Ur element, I have employed many of the same methods but focused on SL1 trans-splicing. 
To test the significance of mutating the Ou element of nduf2.2 on trans-splicing efficiency, I 
assayed trans-splicing using mutant and wild-type RNA constructs treated with the same in vitro 
splicing reaction. The resulting RNA was reverse transcribed. The cDNA was PCR amplified 
with the SL1 primer, thus isolating all SL1 trans-spliced products.    
 Figure 6 shows a schematic of the SL1 primer aligned with its complementary region of 
SL1 trans-spliced mRNA. The red box symbolizes the SL1 leader sequence and the dotted line 
represents the expected product for the primer system. In vivo cis-splicing out-competes trans-
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splicing at intronic splice sites. In vitro, however, splicing occurs post-transcriptionally and 
trans-splicing machinery is in higher abundance relative to cis-splicing machinery than in vivo. 
As a result, a number of trans-spliced products are observed that are not seen in vivo. In addition 
to trans-splicing to the first exon, trans-splicing to the second and third exons is observed in 
vitro. Cis-splicing is also not 100% efficient. As a result products with varying degrees of cis-
splicing (cDNA in which no introns are present, both introns are present, or only one intron is 
present) are observed. Figure 6 outlines all of the potential SL1 trans-spliced products that can 
occur in vitro. Products in which only intron 1 has been removed and products in which only 
intron 2 has been removed are equivalent in size (533 and 532 nt respectively) so in agarose gels 
(Figures 7-9 and 11-13) both products appear as the same band. A schematic of the mRNA in 
which only intron 2 has been removed is used to represent both products.  
 
 
 
Figure 6: In vitro trans-spliced products of nduf2.2 
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Figure 7. Mutating the Ou element may reduce trans-splicing efficiency in vitro. First trans-splicing reaction 
comparing SL1 trans-spliced RNA in wild-type and mutant.  
 
 Figure 7 demonstrates the results of this first trans-splicing reaction comparing wild-type 
and mutant 1 substrates. As expected, all ATP minus lanes are blank indicating that ATP is 
required for splicing and the products observed in the SL1 ATP+ lanes have been spliced. The 
cDNA minus lane is also blank confirming there were no contaminants present in the PCR 
reactions. All SL2 lanes are also blank indicating that no splicing of SL2 to nduf2.2 occurs in 
vitro regardless of the presence or absence of the Ou element.  
 In Figure 7 the only observable products are SL1 trans-spliced in the ATP positive 
reactions for both wild-type and mutant 1 constructs. Focusing first on the products in which SL1 
trans-splicing to exon 1 occurred (the top three bands); these results clearly demonstrate that 
mutating the Ou element decreases trans-splicing efficiency in vitro. The intensity of the bands 
representing trans-splicing to exon 1 is greatly decreased in the mutant 1 reaction. As expected, 
trans-splicing to exon 2 (the middle two bands) does not seem to be affected by the mutation. 
Trans-splicing to exon 3 (the lower band in the second lane), however, is evident for mutant 1 
but not for wild-type samples. These results suggest that mutating the Ou element considerably 
decreased trans-splicing efficiency at the expected SL1 trans-splice site and that exons may 
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compete for SL1 trans-splicing in vitro. The effect of the mutation on trans-splicing to the first 
exon supports my hypothesis that the Ou element plays an important role in SL1 trans-splicing. 
  
Figure 8. Second trans-splicing reaction comparing SL1 trans-spliced RNA of wild-type and mutant samples.  
 
 In a second trans-splicing reaction repeated exactly as before, SL1 trans-splicing levels 
appear to be equivalent at all exons for wild-type and mutant 1 samples (Figure 8). One possible 
explanation for this is that PCR amplification levels had reached a maximum value for both 
samples, thus rendering differences between the reactions indiscernible. It is possible that the 
second trans-splicing reaction was slightly more efficient than the first due to such factors as 
slightly different incubation or setup times/temperatures such that 35 cycles of amplification may 
have been enough to cause the concentration of products to reach the same level and then stop 
being amplified appearing equivalent regardless of the relative amounts of SL1 trans-spliced 
product in each sample. 
  To test this hypothesis, results from the same trans-splicing reaction were compared at 
varying cycles of amplification. Figures 9 and 10 confirm this hypothesis by demonstrating that 
mutant 1 and wild-type samples differ more drastically in observable trans-spliced product when 
the PCR cycle number is reduced. cDNA samples from the second trans-splicing reaction were 
re-amplified at 30, 31, and 32 cycles. For these samples, differences in trans-splicing efficiency 
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at the trans-splice site between wild-type and mutant 1 samples are evident for all, but most 
obvious at 30 cycles of amplification. This difference is more easily observed in Figure 10. This 
graph represents trans-splicing to exon 1 in mutant 1 samples as a percentage of trans-splicing to 
exon 1 in wild-type samples. Figures 9 and 10 show data indicating that the mutant 1 and wild-
type constructs in the second splicing reaction are not equal in SL1 trans-splicing efficiency. In 
fact, results from the second trans-splicing reaction agree with those of the first trans-splicing 
reaction (Figure 7). SL1 trans-splicing levels are considerably decreased when the Ou element is 
mutated. This once again suggests that the Ou element is important for SL1 trans-splicing 
efficiency.  
 
Figure 9. SL1 trans-spliced RNA from the second trans-splicing reaction amplified at a varying number of cycles. 
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Figure 10. Graphical representation comparing levels of SL1 trans-splicing to exon 1 using data from Figure 9.  The 
intensity of the bands representing trans-spliced RNA is expressed as a relative percentage with wild-type trans-
splicing levels set at 100%. 
 
 
 The results from the first two splicing reactions clearly demonstrate that when mutant 1 
and wild-type constructs are compared, mutating the Ou element greatly decreases SL1 trans-
splicing at the trans-splice site. Unlike the first reaction, however, the data shown in Figure 9 
suggests that levels of trans-splicing to exon 2 (demonstrated by the lower two bands) may 
actually be higher in mutant 1 than wild-type samples. It is possible that trans-splice sites 
compete in vitro and, when trans-splicing to the exon 1 is decreased in mutant 1 samples, trans-
splicing to exon 2 (and/or 3) increases. An alternative explanation, however, is that exon 2 trans-
spliced product is being preferentially amplified in the absence of exon 1 trans-spliced product in 
mutant 1 reactions.  
 To differentiate between these hypotheses, I designed a PCR primer that selects for and 
only amplifies product in which trans-splicing occurred to the second exon. This primer, called 
“2E2” (for “to exon 2”), contains the SL1 leader sequence plus the first several bases of the 
second exon. A second PCR primer was created to examine base levels of nduf2.2 construct 
Gallegos, 24 
 
cDNA present in the samples. This forward primer lies within the second exon and is designated 
“IC” (for internal control). The IC primer amplifies all nduf2.2 cDNA present in the sample, thus 
affirming that the same amount of total sample is present in both mutant and wild-type reactions. 
As with the SL1 primer set, both 2E2 and IC primers were used in conjunction with a reverse 
primer downstream of the gene nduf2.2 in the pBluescript plasmid. Schematic diagrams of the 
products amplified by the 2E2 and IC primers are included in Figure 11.  
  Figure 11 shows results from the third trans-splicing reaction comparing wild-type and 
mutant 1 samples amplified by the SL1, 2E2, and IC primer sets. According to these results, not 
only is trans-splicing to exon 1 decreased when the Ou element is mutated (first four lanes 
labeled SL1), but trans-splicing to exon 2 may also be affected (lanes labeled 2E2). The last two 
lanes (labeled IC) in Figure 11 confirm that base levels of nduf2.2 cDNA present in mutant 1 
versus wild-type samples are equivalent by demonstrating that an internal control independent of 
splicing appears at the same intensity in mutant and wild-type samples. This control is significant 
as it demonstrates that decreased levels of trans-splicing in mutant 1 samples are not attributable 
to a decrease in total RNA present in the sample. In conclusion, differences in trans-splicing to 
exon 1 between wild-type and mutant 1 constructs are attributable to the mutation in the Ou 
element. Further, mutating the Ou element may also affect trans-splicing to exon 2 in vitro. 
Results regarding splicing to exon 2, however, are inconsistent among the three splicing 
reactions, making it difficult to draw conclusions. 
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Figure 11. Third trans-splicing reaction comparing SL1 trans-spliced RNA in wild-type and mutants confirms that 
mutating the Ou element decreases trans-splicing to exon 1 and indicates it may also affect trans-splicing to exon 2. 
 
 There are two possible explanations for the decrease in SL1 trans-splicing observed in 
mutant 1 samples. The mutation either disrupted an important sequence (presumably the Ou 
element), or introduced an inhibitory sequence (ACAAUU) that interferes with the process of 
trans-splicing by an unknown mechanism. In order to distinguish between these possibilities, I 
designed a second mutant that also disrupted the Ou consensus but has the sequence GUGGUU 
(see Figure 2 for summary of wild-type and mutant constructs). As with mutant 1, mutant 2 was 
transcribed spliced in vitro. I then performed an RT-PCR of mutant 2 and wild-type reactions, 
amplifying samples with SL1, 2E2, and IC primers. Two different splicing reactions were 
assayed comparing SL1 trans-splicing efficiency for mutant 2 and wild-type constructs. The 
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results from both are consistent. Mutant 2 also decreased trans-splicing efficiency supporting the 
hypothesis that the Ou element is necessary for trans-splicing. The results for mutant 2 reactions 
are shown in Figures 12 and 13.  
 
Figure 12. Mutant 2 also decreases SL1 trans-splicing. Results from first trans-splicing reaction comparing SL1 
trans-spliced RNA in the wild-type and mutant 2. 
 
 
 
Figure 13. Results from a second trans-splicing reaction comparing SL1 trans-spliced RNA in wild-type and mutant 
2 constructs including 2E2 and IC primed samples.  
 
 Figure 13 confirms that a second mutation in the Ou element of nduf2.2 also decreased 
SL1 trans-splicing. According to 2E2 PCR reactions, SL1 trans-splicing to exon 2 is comparable 
for wild-type and mutant 2 samples. Results regarding trans-splicing to exon 2 are inconsistent 
and therefore inconclusive. Results comparing trans-splicing to the trans-splice site in wild-type, 
mutant 1, and mutant 2 samples, however, are consistent. Mutating the Ou element decreases 
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trans-splicing efficiency in vitro. These results indicate that the predicted Ou element was 
correctly identified and that it is important for SL1 trans-splicing. 
 
 
Discussion 
 To test the relevance of the predicted Ou element for SL1 trans-splicing in vitro, I 
introduced mutations to the proposed Ou consensus in an nduf2.2 construct. I then subjected the 
mutant and wild-type samples to an in vitro trans-splicing assay with embryonic extract capable 
of splicing. A cDNA copy was made of the spliced RNA samples and those containing the SL1 
leader sequence were selected for and amplified. The amount of trans-spliced product for mutant 
versus wild-type samples was compared. After this initial examination I designed a second 
mutant with the similar goal of testing the importance of the predicted Ou element in SL1 trans-
splicing. The purpose of the second mutant is to ensure that the absence of the Ou element is the 
variable affecting trans-splicing, and not the introduction of a new sequence that is somehow 
deleterious. Control PCR reactions were included to demonstrate that the same amount of DNA 
was present in both mutant and wild-type samples and that cis-splicing levels were consistent 
from wild-type to mutant, thus allowing any differences observed to be attributed to the effect of 
the mutations on trans-splicing efficiency. 
 Results comparing SL1 trans-splicing of mutant 1 and wild-type samples were consistent. 
In three different trans-splicing reactions, mutant samples exhibited considerably less product in 
which the SL1 leader was trans-spliced onto the first exon of nduf2.2 (Figures 7, 9, and 11). 
These results suggest that in vitro trans-splicing to the nduf2.2 trans-splice site was considerably 
less successful for nduf2.2 constructs lacking an Ou consensus sequence than those with the 
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proposed Ou element still intact. It must also be taken into consideration, however, whether or 
not the mutation introduced a sequence that is inhibitory to SL1 trans-splicing. To account for 
this, the same procedures used to test mutant 1 were repeated for a second mutant, mutant 2. 
Once again in two different trans-splicing reactions, trans-splicing to exon 1 was decreased in 
mutant 2 samples as compared to wild-type (Figures 12 and 13). These data support the 
hypothesis that the decreases in trans-splicing efficiency observed in vitro are attributable to the 
disruption of the proposed Ou consensus sequence. In conclusion, various samples from five 
different splicing reactions comparing SL1 trans-spliced products in mutant versus wild-type 
samples all agree. Mutating the sequence UGUUUU in the gene nduf2.2 significantly reduces 
SL1 trans-splicing efficiency in vitro.  
 It is important to note that trans-splicing was decreased in mutant reactions, but never 
completely knocked down. One reason for this might be the redundancy of the Ou element. As 
previously mentioned, in addition to the proposed Ou element (UGUUUU), there were several 1-
3 base mismatches to the URYYUY consensus overlapping or nearby. Lasda et al. (2010) 
noticed similar patterns in redundancy among Ur elements in the intercistronic region (ICR) of 
SL2 trans-spliced genes. When all copies of the UR consensus were mutated, however, SL2 
trans-splicing was almost entirely lost. It is possible that if a similar experiment was repeated for 
the Ou element, results would indicate that it too acts redundantly. 
 In vivo experiments could also be conducted to test the necessity of the Ou element in 
SL1 trans-splicing. Such a project would involve creating transgenic C. elegans strains in which 
the Ou element was mutated. Huang et al. (2001) used such techniques to demonstrate the 
necessity of the Ur element in SL2 trans-splicing in vivo. They introduced linker scan (LS) 
mutations to the ICR between genes in an operon. They found that for LS mutants in which the 
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Ur element (which was previously unidentified) was disrupted, accumulation of mRNA from 
genes downstream in the operon was significantly reduced. They also found that when the Ur 
element was mutated and 3’ cleavage of the upstream gene was prevented, SL1-trans-splicing 
increased. It is now known that the UR element includes the sequence UAYYUU as well as a 
stem-loop just upstream (Lasda et al., 2010). When cleavage of the 3’ end of the upstream gene 
occurs, a 5’ phosphate in the ICR is exposed. In the absence of a Ur element, this uncapped 
mRNA is rapidly degraded by XRN2 exonuclease until transcription is halted. When the Ur 
element is intact, however, the stem loop may prevent degradation, allowing SL2 trans-splicing 
to occur. This schematic is demonstrated in Figure 14. 
 
 
 
Figure 14. Model for the relationship between the Ur element, SL1, and SL2 trans-splicing 
 
Gallegos, 30 
 
 Unlike ICR’s, outrons have not been shown to assume any particular secondary structure. 
In fact, UA rich intron-like sequence in which the 5’ splice site has been removed is sufficient 
for SL1 trans-splicing in vivo (Conrad et al., 1991 & 1993). It may be that in the absence of the 
stem-loop structure the ICR acts like an intron. Interestingly, the Ur element (UAYYUU) also 
satisfies the Ou consensus (URYYUY). Thus SL1 trans-splicing may act as a default in the 
absence of the stem-loop structure. 
 Prior to this study, the sequence of the Ou element had been loosely defined. The 
hypothesized sequence URYYUY was derived for its ability to base pair with the 5’ splice site 
on the SL1 spliced leader. A bioinformatic analysis by Graber et al. (2007) confirmed the 
existence of an outron-specific UC-rich sequence. Previously, however, no work had been done 
to experimentally test the significance of the sequence. The results presented here on trans-
splicing to exon 1 of nduf2.2 suggest that the Ou element for this gene has been correctly 
identified and that it is in fact necessary for efficient SL1 trans-splicing in vitro. 
 In addition to providing evidence for the role of the Ou element in SL1 trans-splicing, 
this study raises interesting questions about the trans-splicing dynamics observed in the in vitro 
splicing system used. The results achieved by using this splicing system agree with those 
reported by Lasda et al. (2010) who first reported the successful use of C. elegans embryonic 
extract to splice pre-mRNA in vitro. Splicing specificity seen in vivo was recapitulated in my in 
vitro analysis. The wild-type construct of the gene nduf2.2 was spliced exclusively to SL1 leader 
sequence. Furthermore, it was found that even when SL1 trans-spliced product decreased (in the 
case of the mutant constructs), no SL2 spliced product was apparent. This means that SL2 
splicing is not compensating for the decrease in SL1 trans-splicing achieved by mutating the Ou 
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element in vitro. As previously described, this may be due to the lack of the stem-loop structure 
required for SL2 trans-splicing. 
 Interestingly, there was an unexpected fluctuation in trans-splicing to exons 2 and 3 when 
the Ou element was mutated. Lasda et. al. (2010) observed similar cases of trans-splicing to cis-
splice sites in the in vitro system, but did not specifically isolate these products. In the first trans-
splicing reaction, trans-splicing to exon 3 was apparent for mutant 1 but not wild-type constructs 
(Figure 7). One possible explanation suggests that exons may be competing for trans-splicing in 
this in vitro system. In vivo, nduf2.2 is SL1 trans-spliced exclusively at the first exon. The in 
vitro system used, however, may have trouble distinguishing between the actual trans-splice site 
and the intronic cis-splice sites since splicing is occurring post-transcriptionally. Interestingly, 
there are sequences that satisfy the Ou consensus in both the first and second intron (sequences 
TACTTT and TATTTC respectively). Especially when the Ou element in the outron is mutated, 
the in vitro trans-splicing machinery may be recognizing the downstream Ou consensus 
sequences by mistake; however, these sequences are very near the 3’ splice site while the Ou 
consensus is typically found approximately 50 bp upstream of the splice site (Graber et al. 2007). 
 In the first trans-splicing reaction, trans-splicing to exon 2 appears to be occurring at 
equal frequencies for wild-type and mutant 1 samples (Figure 7). The second trans-splicing 
reaction, on the other hand, demonstrates an increase in trans-splicing to exon 2 in mutant 1 
samples (Figures 8 and 9). Furthermore, the first trans-splicing reaction of mutant 2 suggests that 
trans-splicing to exon 2 is decreased for mutant samples (Figure 12). These inconsistencies 
regarding levels of SL1 trans-splicing to exon 2 make it difficult to draw conclusions.  
 I designed the 2E2 primer to test the hypothesis that trans-splicing to the second exon 
was not occurring at greater or equal levels in the mutant, but that these cDNA species were 
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being preferentially amplified in mutant samples in the absence of cDNA in which trans-splicing 
to exon 1 occurred. Results from the third trans-splicing reaction were analyzed to compare 
trans-splicing to exon 2 exclusively between wild-type and mutant 1 samples. The 2E2 PCR 
reactions, revealed that there was actually more product in which the SL1 leader sequence was 
trans-spliced to exon 2 for wild-type than for mutant samples (Figure 11). It is therefore possible, 
that trans-splicing to exon 2 is also reduced in mutant samples but to a lesser degree than trans-
splicing to exon 1. One possible explanation for this result is that trans-splicing to exon 2 is also 
affected by the presence versus absence of the Ou element. This explanation is plausible as the 
Ou element is only 223 bases from the start of exon 2.  
 When mutant 2 was similarly analyzed with the 2E2 primer, however, trans-splicing to 
exon 2 was approximately equivalent for wild-type and mutant 2 samples (Figure 13). Thus, 
even when trans-splicing to exon 2 was specifically isolated results were inconsistent. These 
conflicting data make it impossible to determine from these results whether trans-splicing to the 
second exon seen in vitro is affected by the presence or absence of the Ou element. Nonetheless, 
these data raise interesting questions regarding the range of influence of the Ou element. At what 
position upstream of the trans-splice site is the Ou element most effective at mediating trans-
splicing? In order to answer this question, in vitro trans-splicing reactions in which the Ou 
element occupied various different locations could be compared.  
 Further research to investigate the correlation between the Ou element and SL1 trans-
splicing might also include exploration of additional mutants. The results presented here suggest 
that the Ou element is necessary for SL1 trans-splicing, but say nothing of its sufficiency. If the 
Ou element is also sufficient in directing trans-splicing, then a different sequence from the wild-
type that still satisfies the Ou consensus sequence would be predicted to restore SL1 trans-
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splicing efficiency to the same level as wild-type. Additionally a synthetic outron containing and 
lacking an Ou element should demonstrate stark differences in levels of SL1 trans-splicing.  
 To identify the specific function of the Ou element, analogous experiments with the SL1 
snRNP are necessary. If the Ou element acts by base pairing with the 5’ splice site on the SL1 
RNA as predicted, then mutating the sequence complementary to the Ou (GAGGUA) should 
exhibit similar decreases in SL1 trans-splicing efficiency. Likewise, introducing a compensatory 
mutation to the Ou element of the mRNA to be trans-spliced should restore trans-splicing levels. 
Although the results of this study have greatly advanced current understanding of the 
requirements for SL1 trans-splicing in vitro, various other such experiments are necessary to 
reveal more about the direct role of the Ou element. 
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